Salute e Benessere

Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific…

"As a leader in hematologic malignancies, AbbVie is committed to advancing innovative treatments for complex cancers like multiple myeloma through our relentless R&D efforts and collaborations," said Mariana Cota Stirner, M.D., Ph.D., vice president, therapeutic area head for hematology, AbbVie. "We look forward to partnering with Simcere Zaiming, to advance this novel trispecific antibody, which has the potential to help address significant unmet medical needs for people…
PR Newswire
13/01/2025

ERS Genomics launches 'Express License' platform to democratise access to…

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An Express License provides fast, simple and affordable access to the CRISPR/Cas9 patent portfolio through a non-exclusive internal research license. DUBLIN and CHESHIRE, United Kingdom, Jan.13, 2025(GLOBE NEWSWIRE) -- ERS Genomics ('ERS'), the CRISPR licensing company, today announces the launch of its Express License platform to provide small research...
Nasdaq GlobeNewswire
13/01/2025

ZEISS MEL 90 excimer laser receives U.S. FDA approval; completes Corneal…

"The increasing global adoption of laser vision correction reflects the advancements and positive impact the technology continues to have on the quality of life for patients," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "With the integration of the ZEISS MEL 90, surgeons can confidently care for their patients with greater workflow efficiency and performance with enhanced outcomes." "The increasing global adoption…
PR Newswire
13/01/2025

Novo Nordisk A/S - share repurchase programme

Bagsværd, Denmark, 13 January 2025– On 11 November 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024.Under…
Nasdaq GlobeNewswire
13/01/2025

Q'Apel Medical Announces CE Mark Approval for Armadillo SelectFlex™…

The Armadillo Neurovascular Access System with SelectFlex™ Technology delivers the versatility required for physicians to confidently tackle a wide range of neurovascular interventions. Regardless of access site, the low-profile 7F catheter enables a biaxial approach to accelerate delicate interventions and eliminate the complexity and cost of conventional tri-axial configurations. The Armadillo Neurovascular Access System with SelectFlex™ Technology delivers the versatility...
PR Newswire
13/01/2025

KFSHRC Modernizes Biobank Center… Ushering an Era of Personalized Medicine

RIYADH, Saudia Arabia, Jan.13, 2025(GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Center (KFSHRC) has announced the modernization of its Biobank Center, marking a significant milestone in healthcare and medical research within the Kingdom. This modernization aligns with the healthcare goals of Saudi Vision 2030, which emphasize prevention, public health, innovation, and the long-term sustainability of medical research. The Biobank Center aims to accelerate...
Nasdaq GlobeNewswire
13/01/2025

ITM and Ariceum Therapeutics Enter Into Supply Agreement for Therapeutic Medical…

Garching / Munich / Berlin, Germany, January 13, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced the execution of a supply agreement for non-carrier-added (n.c.a.) Actinium-225 (Ac-225) to support the development of Ariceum's novel targeted...
Nasdaq GlobeNewswire
13/01/2025

X4 Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to…

X4 to receive a €28.5 million upfront payment and up to €226 million in potential regulatory and commercial milestone payments in addition to tiered, double-digit royalties up to the mid-twentiesUpfront non-dilutive funds strengthen X4's balance sheet as enrollment ramps up in the company's global Phase 3 clinical trial in chronic neutropenia Agreement underscores Norgine's commitment to bring transformative therapies to patients in need in these key strategic territories BOSTON and...
Nasdaq GlobeNewswire
13/01/2025

Endo Launches New Peyronie's Disease Campaign: I Got Somebody

The commercial begins with a man searching online for answers to his PD-related questions, highlighting the anxiety, distress, and isolation he feels. As the story unfolds, a series of mishaps occur, with the man's peers confidently recommending solutions for a broken windshield, raccoon infestation, pulled garden plants, overflowing washing machine, and a smoking car engine. Finally, the protagonist asks his friends if they know someone who can help with his PD concerns. Thecommercial...
PR Newswire
13/01/2025

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer

Amphista Therapeutics appoints Paul Medeiros as Chief Business Officer Appointment supports the Company's ambitions to advance its portfolio ofnext generation Targeted Glue™ protein degrader therapeutics andto accelerate its overall corporate development Cambridge, UK, 13 January 2025– Amphista Therapeutics, a leader in the discovery of next-generation, Targeted, Protein Degradation (TPD) medicines, today announces the appointment of Paul Medeiros as Chief Business Officer (CBO)...
Nasdaq GlobeNewswire
13/01/2025

Rappta Therapeutics enters into a global license agreement with SpringWorks…

PP2A mutations are oncogenic drivers in molecularly defined subsets of uterine cancer and represent a targetable subset of patients with a high unmet clinical need. In pre-clinical models of PP2A mutant uterine cancer, RPT0402 achieved rapid, deep and durable tumor regressions at as monotherapy. PP2A mutations are oncogenic drivers in molecularly defined subsets of uterine cancer and represent a targetable subset of patients with a high unmet clinical need. In pre-clinical models of PP2A…
PR Newswire
13/01/2025

CBC Group's R-Bridge Announces US$40M Synthetic Royalty-Backed Financing for…

- Transaction underscores R-Bridge's commitment to advancing life sciences innovations and expanding access to high-quality medical care - Transaction underscores R-Bridge's commitment to advancing life sciences innovations and expanding access to high-quality medical care SINGAPORE , Jan. 13, 2025 /PRNewswire/ -- CBC Group's R-Bridge Healthcare Fund ("R-Bridge") announces aUS$40 millionstructured financing transaction with Mirxes Pte Ltd., aSingapore -based miRNA technology...
PR Newswire
13/01/2025

XingImaging Opens State-of-the-Art Research Facility in New Haven, Connecticut

"We are proud to open this facility in the City of New Haven, a hub for research and healthcare innovation," said Gilles Tamagnan, CEO of XingImaging. "The new facility represents a significant leap forward in our mission to deliver high-quality imaging solutions and accelerate the development of life-saving treatments. Our commitment to quality is reflected in every aspect of our research, from the radiotracer manufacturing process to the meticulous analysis of clinical imaging…
PR Newswire
13/01/2025

Major shareholder announcement due to closing of ITC Logistic GmbH

Company announcement no. 1 – 2513 January 2025 Major shareholder announcement due to closing of ITC Logistic GmbH Pursuant to Section 31 of the Danish Capital Markets Act, it is hereby announced that NTG Nordic Transport Group A/S (“NTG”) as of 10 January 2025 owns a total of 954,723 treasury shares of nominally DKK 20 (in total nominally DKK 19,094,460), hereby reducing its holding of treasury shares to less than 5% of the total share capital of NTG.The decrease in treasury shares is...
Nasdaq GlobeNewswire
13/01/2025

Outrun Therapeutics expands leadership team with appointment of Matthew Fyfe as…

At Outrun, he will be responsible for the advancement of the Company's therapeutics portfolio derived from its novel, proprietary X-E3L (Crosslinking E3 Labeller) technology platform which accelerates the discovery of first-in-class small molecule protein stabilising drugs targeting E3 ligases. At Outrun, he will be responsible for the advancement of the Company's therapeutics portfolio derived from its novel, proprietary X-E 3 L (Crosslinking E3 Labeller) technology platform which…
PR Newswire
13/01/2025

SYNERGIA MEDICAL ANNOUNCES: FIVE PATIENTS NOW IMPLANTED WITH NAO.VNS™ LEADERSHIP…

TMsystem in three more patients, bringing the total to five, as part of the AURORA study. These First-In-Human implantations took place at Cliniques Universitaires Saint-Luc and UZ Gent, Belgium. All patients have fully recovered, allowing the initiation of stimulation therapy as planned.Early patient responses are highly promising, and full results from these first clinical trials are expected in the next few weeks. The Board of Directors of Synergia Medical has appointed Mr. Charles...
Nasdaq GlobeNewswire
13/01/2025

Diamyd Medical updates U.S. market potential for Diamyd®

Addressable market at launch Addressable market at launch The addressable market for Diamyd® at launch consists of two distinct populations, both comprising patients aged 12 years and older. These combined populations will annually total over 60,000 patients in the U.S. the coming years when accounting for incidence and population growth. Market assumptions Clear growth drivers and upsides The market research underscores the importance of enhancing Health Care Practitioner...
PR Newswire
13/01/2025

79,345 Orion Corporation A shares converted into B shares

ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 13 JANUARY 2025 at 9.50 EET 79,345 Orion Corporation A shares converted into B shares In accordance with Section 3 of the Articles of Association of Orion Corporation, 79,345 A shares have been converted into 79,345 B shares. The conversion has been entered into the Trade Register on 13 January 2025.The total number of shares in Orion Corporation is 141,134,278...
Nasdaq GlobeNewswire
13/01/2025

ONWARD Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

CEO Dave Marver to Provide Company Update Wednesday, January 15, 2025 Wednesday, January 15 at 1:30pm Eastern Time (10:30am Pacific Time / 7:30pm Central European Time). The Company presentation and Q&A session will be webcast live, and an archive recording will be available for 30 days. The link to the live webcast and archive will be accessible on ONWARD Medical's investor website located athttps://ir.onwd.com/news-eventsAbout ONWARD Medical ONWARD Medical is a medical...
Nasdaq GlobeNewswire
13/01/2025

Novartis Entresto® US patent upheld by US Court of Appeals

Basel, January 13, 2025– Novartis is pleased with the decision by the US Court of Appeals for the Federal Circuit (CAFC) that affirms the validity of the Entresto ®(sacubitril/valsartan) combination patent.We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025. We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto.There are currently no...
Nasdaq GlobeNewswire
13/01/2025

W. L. GORE & ASSOCIATES, INC. RECEIVES CE MARK FOR LOWER PROFILE GORE® VIABAHN®…

Medical Device Regulation (MDR) approval of this innovation builds on a proven device which has become an important tool for treating complex vascular disease.* In addition to offering the longest balloon expandable stent on the market with its 79 mm configuration, and the widest range of stent diameter adjustability, the VBX Stent Graft now also offers the most 6 Fr compatible configurations.1–5 Medical Device Regulation (MDR) approval of this innovation builds on a proven device which has...
PR Newswire
13/01/2025

Teva Announces Collaboration to Commercialize Formycon's Biosimilar Candidate to…

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ®1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ®2(ranibizumab) in EuropeThe partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategyTEL AVIV, Israel, Jan.13, 2025(GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a...
Nasdaq GlobeNewswire
13/01/2025

Press Release: Sarclisa obtains first approval in China for the treatment of…

Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myelomaApproval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term outcomes compared to Pd alone in R/R MM patients Sarclisa-Pd is currently recommended by the Chinese Society of Clinical Oncology (CCSCO) and Chinese...
Nasdaq GlobeNewswire
13/01/2025

Idorsia to call for a bondholder meeting

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – January 13, 2025Idorsia Ltd (SIX: IDIA) today announced that – in the coming days – the company intends to publish an invitation to a bondholder meeting for holders of its outstanding convertible bond (ISIN: CH0426820350) (the Bonds or CB 2025) with a nominal value of CHF 200 million and a conversion price of CHF 6.00 per Idorsia share, maturing on January 17, 2025. At the meeting, the company will propose changing the...
Nasdaq GlobeNewswire
13/01/2025
Altri  Comunicati